within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02C_AntiadrenergicAgentsPeripherallyActing.C02CC01_Betanidine;

model Betanidine
  extends Pharmacolibrary.Drugs.ATC.C.C02CC01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C02CC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Betanidine is a sympatholytic antihypertensive agent from the guanidine class, formerly used to manage high blood pressure. It acts by inhibiting the release of norepinephrine from sympathetic nerve endings, leading to vasodilation and reduced blood pressure. Betanidine is rarely used today due to its unfavorable side effect profile and the availability of newer antihypertensive medications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on analogous guanidine antihypertensives (e.g., guanethidine, debrisoquine), as no clinical human PK studies of betanidine have been published. Suggested parameters are for healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Dring, LG, et al., &amp; Smith, RL (1977). Absence of correlation between the oral pharmacokinetics and response to bethanidine [proceedings]. <i>British journal of clinical pharmacology</i> 4(3) 390P–391P. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1977.tb00738.x\">10.1111/j.1365-2125.1977.tb00738.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/901715/\">https://pubmed.ncbi.nlm.nih.gov/901715</a></p></li><li><p>Shen, D, et al., &amp; McNay, J (1975). Pharmacokinetics of bethanidine in hypertensive patients. <i>Clinical pharmacology and therapeutics</i> 17(3) 363–373. DOI:<a href=\"https://doi.org/10.1002/cpt1975173363\">10.1002/cpt1975173363</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1120401/\">https://pubmed.ncbi.nlm.nih.gov/1120401</a></p></li><li><p>Parker, SG, et al., &amp; Eden, RJ (1994). Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist. <i>European journal of pharmacology</i> 265(1-2) 17–26. DOI:<a href=\"https://doi.org/10.1016/0014-2999(94)90218-6\">10.1016/0014-2999(94)90218-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7883025/\">https://pubmed.ncbi.nlm.nih.gov/7883025</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Betanidine;
